본문 바로가기
KERD
논문KCI 등재

Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?

김원재
대한배뇨장애요실금학회 (Korean Continence Society)|2015.06|International Neurourology Journal|제19권 제2호|pp. 55-66

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

MetabolismUrinary Bladder NeoplasmsAMP-Activated Protein Kinases

초록

The 5´-AMP-activated protein kinase (AMPK) is a key regulator of cellular metabolism and energy homeostasis in mammalian tissues. Metabolic adaptation is a critical step in ensuring cell survival during metabolic stress. Because of its critical role in the regulation of glucose homeostasis and carbohydrate, lipid, and protein metabolism, AMPK is involved in many human diseases, including cancers. Although AMPK signaling was originally characterized as a tumor-suppressive signaling pathway, several lines of evidence suggest that AMPK plays a much broader role and cannot simply be defined as either an oncogenic regulator or tumor suppressor. Notably, several recent studies demonstrated that the antitumorigenic effects of many indirect AMPK activators, such as metformin, do not depend on AMPK. Conversely, activation of AMPK induces the progression of cancers, emphasizing its oncogenic effect. Bladder cancer can be divided into two groups: non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The molecular mechanisms underlying these two types of cancer are distinct: NMIBC is associated with activation of the Ras pathway, whereas MIBC is characterized by loss of major tumor suppressors. Importantly, both pathways are connected to the mammalian target of rapamycin (mTOR) pathway. In addition, our recent metabolomic findings suggest that β-oxidation of fatty acids is an important factor in the development of bladder cancer. Both mTOR and β-oxidation are tightly associated with the AMPK pathway. Here, I summarize and discuss the recent findings on the two distinct roles of AMPK in cancer, as well as the relationship between bladder cancer and AMPK.

Abstract

The 5´-AMP-activated protein kinase (AMPK) is a key regulator of cellular metabolism and energy homeostasis in mammalian tissues. Metabolic adaptation is a critical step in ensuring cell survival during metabolic stress. Because of its critical role in the regulation of glucose homeostasis and carbohydrate, lipid, and protein metabolism, AMPK is involved in many human diseases, including cancers. Although AMPK signaling was originally characterized as a tumor-suppressive signaling pathway, several lines of evidence suggest that AMPK plays a much broader role and cannot simply be defined as either an oncogenic regulator or tumor suppressor. Notably, several recent studies demonstrated that the antitumorigenic effects of many indirect AMPK activators, such as metformin, do not depend on AMPK. Conversely, activation of AMPK induces the progression of cancers, emphasizing its oncogenic effect. Bladder cancer can be divided into two groups: non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The molecular mechanisms underlying these two types of cancer are distinct: NMIBC is associated with activation of the Ras pathway, whereas MIBC is characterized by loss of major tumor suppressors. Importantly, both pathways are connected to the mammalian target of rapamycin (mTOR) pathway. In addition, our recent metabolomic findings suggest that β-oxidation of fatty acids is an important factor in the development of bladder cancer. Both mTOR and β-oxidation are tightly associated with the AMPK pathway. Here, I summarize and discuss the recent findings on the two distinct roles of AMPK in cancer, as well as the relationship between bladder cancer and AMPK.

참고문헌 (100)

  1. Bergeron R, "Effect of AMPK activation on muscle glucose metabolism in conscious rats", Am J Physiol, 276(5 Pt 1), pp.E938~E944 (1999)
  2. Durante PE, "Effects of endurance training on activity and expression of AMP-activated protein kinase isoforms in rat muscles", Am J Physiol Endocrinol Metab, 283, pp.E178~E186 (2002)
  3. Ojuka EO, "Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle", Proc Nutr Soc, 63, pp.275~278 (2004)
  4. Thomson DM, "Skeletal muscle and heart LKB1 deficiency causes decreased voluntary running and reduced muscle mitochondrial marker enzyme expression in mice", Am J Physiol Endocrinol Metab, 292, pp.E196~E202 (2007)
  5. Faubert B, "The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator", Cancer Lett, 356(2 Pt A), pp.165~170 (2015)
  6. Hardie DG, "LKB1 and AMPK and the cancer-metabolism link - ten years after", BMC Biol, 11, pp.36~ (2013)
  7. Jeon SM, "The dark face of AMPK as an essential tumor promoter", Cell Logist, 2, pp.197~202 (2012)
  8. Liang J, "AMPK: a contextual oncogene or tumor suppressor", Cancer Res, 73, pp.2929~2935 (2013)
  9. Alfarouk KO, "Tumor acidity as evolutionary spite", Cancers (Basel), 3, pp.408~414 (2011)
  10. Gatenby RA, "Why do cancers have high aerobic glycolysis", Nat Rev Cancer, 4, pp.891~899 (2004)
  11. Kim JW, "Cancer’s molecular sweet tooth and the Warburg effect", Cancer Res, 66, pp.8927~8930 (2006)
  12. Lopez-Lazaro M, "The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen", Anticancer Agents Med Chem, 8, pp.305~312 (2008)
  13. White E, "Deconvoluting the context-dependent role for autophagy in cancer", Nat Rev Cancer, 12, pp.401~410 (2012)
  14. Yang D, "Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L)", Cancer Biol Ther, 9, pp.122~133 (2010)
  15. Bando H, "Phosphorylation of the 6-phosphofructo-2-kinase", fructose 2,6-bisphosphatase, Clin Cancer Res, pp.2005, 11[DOI]
  16. Mendoza EE, "Control of glycolytic flux by AMP-activated protein kinase in tumor cells adapted to low pH", Transl Oncol, 5, pp.208~216 (2012)
  17. Faubert B, "AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo", Cell Metab, 17, pp.113~124 (2013)
  18. Yi W, "Phosphofructokinase 1 glycosylation regulates cell growth and metabolism", Science, 337, pp.975~980 (2012)
  19. Mizrachy-Schwartz S, "Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation", J Biol Chem, 286, pp.15268~15277 (2011)
  20. Liu L, "Deregulated MYC expression induces dependence upon AMPKrelated kinase 5", Nature, 483, pp.608~612 (2012)
  21. Rios M, "AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors", Cancer Res, 73, pp.2628~2638 (2013)
  22. Tennakoon JB, "Androgens regulate prostate cancer cell growth via an AMPKPGC- 1α-mediated metabolic switch", Oncogene, 33, pp.5251~5261 (2014)
  23. Massie CE, "The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis", EMBO J, 30, pp.2719~2733 (2011)
  24. Frigo DE, "CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells", Cancer Res, 71, pp.528~537 (2011)
  25. Possik E, "Folliculin regulates ampk-dependent autophagy and metabolic stress survival", PLoS Genet, 10, pp.e1004273~ (2014)
  26. Yan M, "The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation", J Clin Invest, 124, pp.2640~2650 (2014)
  27. Bardeesy N, "Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation", Nature, 419, pp.162~167 (2002)
  28. Laderoute KR, "5’-AMP-activated protein kinase (AMPK) is induced by lowoxygen and glucose deprivation conditions found in solid-tumor microenvironments", Mol Cell Biol, 26, pp.5336~5347 (2006)
  29. Fernandez MR, "Kinase suppressor of Ras 2 (KSR2) regulates tumor cell transformation via AMPK", Mol Cell Biol, 32, pp.3718~3731 (2012)
  30. Kato K, "Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation", Oncogene, 21, pp.6082~6090 (2002)
  31. Laderoute KR, "5’-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors", J Biol Chem, 289, pp.22850~22864 (2014)
  32. Hindupur SK, "Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells", Breast Cancer Res, 16, pp.420~ (2014)
  33. Godlewski J, "MicroRNA-451 regulates LKB1", AMPK signaling and allows adaptation to metabolic stress in glioma cells, 2010, pp.37, 620~632
  34. Borgdorff V, "A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF", Oncogene, 33, pp.2531~2539 (2014)
  35. Ros S, "Functional metabolic screen identifies 6-phosphofructo-2-kinase", fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival, 2012, pp.2, 328~343
  36. Jeon SM, "AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress", Nature, 485, pp.661~665 (2012)
  37. She C, "Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: new implications for osteonecrosis treatment", Cell Signal, 26, pp.1~8 (2014)
  38. Hawley SA, "Complexes between the LKB1 tumor suppressor, STRAD alpha", beta and MO25 alpha, J Biol, pp.2003, 2[DOI]
  39. Woods A, "LKB1 is the upstream kinase in the AMP-activated protein kinase cascade", Curr Biol, 13, pp.2004~2008 (2003)
  40. Corradetti MN, "Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome", Genes Dev, 18, pp.1533~1538 (2004)
  41. Inoki K, "TSC2 mediates cellular energy response to control cell growth and survival", Cell, 115, pp.577~590 (2003)
  42. Hemminki A, "A serine", threonine kinase gene defective in Peutz- Jeghers syndrome, 1998, pp.391, 184~187
  43. Shackelford DB, "The LKB1-AMPK pathway: metabolism and growth control in tumour suppression", Nat Rev Cancer, 9, pp.563~575 (2009)
  44. Ji H, "LKB1 modulates lung cancer differentiation and metastasis", Nature, 448, pp.807~810 (2007)
  45. Carretero J, "Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors", Cancer Cell, 17, pp.547~559 (2010)
  46. Xu C, "Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression", Cancer Cell, 25, pp.590~604 (2014)
  47. Dupuy F, "LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer", Cancer Metab, 1, pp.18~ (2013)
  48. Cheng H, "A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition", Cancer Res, 74, pp.15~23 (2014)
  49. Contreras CM, "Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas", Cancer Res, 68, pp.759~766 (2008)
  50. Contreras CM, "Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy", Dis Model Mech, 3, pp.181~193 (2010)
  51. Mohseni M, "A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway", Nat Cell Biol, 16, pp.108~117 (2014)
  52. Goodwin JM, "An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential", Mol Cell, 55, pp.436~450 (2014)
  53. Faubert B, "Svensson RU, et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α", Proc Natl Acad Sci U S A, 111, pp.2554~2559 (2014)
  54. Evans JM, "Metformin and reduced risk of cancer in diabetic patients", BMJ, 330, pp.1304~1305 (2005)
  55. Decensi A, "Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis", Cancer Prev Res (Phila), 3, pp.1451~1461 (2010)
  56. Rosilio C, "The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTENdeficient T cell lymphomas and human T-ALL", T-LL cancer cells, 2013, pp.336, 114~126
  57. El-Masry OS, "Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds", Oncol Lett, 3, pp.224~228 (2012)
  58. Buzzai M, "Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth", Cancer Res, 67, pp.6745~6752 (2007)
  59. Appleyard MV, "Phenformin as prophylaxis and therapy in breast cancer xenografts", Br J Cancer, 106, pp.1117~1122 (2012)
  60. Liu X, "Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK", Proc Natl Acad Sci U S A, 111, pp.E435~E444 (2014)
  61. Shackelford DB, "LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin", Cancer Cell, 23, pp.143~158 (2013)
  62. "Differential effects of AMPK agonists on cell growth and metabolism"[URL]
  63. Steinberg GR, "AMPK in health and disease", Physiol Rev, 89, pp.1025~1078 (2009)
  64. Viollet B, "AMPK inhibition in health and disease", Crit Rev Biochem Mol Biol, 45, pp.276~295 (2010)
  65. Mantovani J, "Re-evaluating the general(ized) roles of AMPK in cellular metabolism", FEBS Lett, 585, pp.967~972 (2011)
  66. Platt FM, "Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer", Clin Cancer Res, 15, pp.6008~6017 (2009)
  67. Dinney CP, "Focus on bladder cancer", Cancer Cell, 6, pp.111~116 (2004)
  68. Mo L, "Hyperactivation of Ha-ras oncogene, but not Ink4a", Arf deficiency, triggers bladder tumorigenesis, 2007, pp.117, 314~325
  69. Sibley K, "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma", Oncogene, 20, pp.686~691 (2001)
  70. Seager CM, "Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer", Cancer Prev Res (Phila), 2, pp.1008~1014 (2009)
  71. He F, "Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis", Cancer Res, 69, pp.9413~9421 (2009)
  72. Chatterjee SJ, "Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma", J Clin Oncol, 22, pp.1007~1013 (2004)
  73. Feng Z, "The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways", Cancer Res, 67, pp.3043~3053 (2007)
  74. Liu Z, "Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy", Mol Carcinog, 51, pp.257~267 (2012)
  75. Papanas N, "Metformin and cancer: licence to heal", Expert Opin Investig Drugs, 19, pp.913~917 (2010)
  76. Zhang T, "Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR", S6K1-mediated downregulation of c-FLIP, 2014, pp.25, 887~897
  77. Yan S, "The PPARγ agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells", Cancer Gene Ther, 21, pp.188~193 (2014)
  78. Hay N, "The Akt-mTOR tango and its relevance to cancer", Cancer Cell, 8, pp.179~183 (2005)
  79. Sabatini DM, "mTOR and cancer: insights into a complex relationship", Nat Rev Cancer, 6, pp.729~734 (2006)
  80. Puzio-Kuter AM, "Inactivation of p53 and Pten promotes invasive bladder cancer", Genes Dev, 23, pp.675~680 (2009)
  81. Qian CN, "Activation of the PI3K", AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models, 2009, pp.69, 8256~8264
  82. Cappellen D, "Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder", Oncogene, 14, pp.3059~3066 (1997)
  83. Pymar LS, "Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms", Hum Mol Genet, 17, pp.2006~2017 (2008)
  84. Jin X, "Diagnosis of bladder cancer and prediction of survival by urinary metabolomics", Oncotarget, 5, pp.1635~1645 (2014)
  85. Kim WJ, "Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer", Mol Cancer, 9, pp.3~ (2010)
  86. Samudio I, "Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction", J Clin Invest, 120, pp.142~156 (2010)
  87. Bebernitz GR, "The impact of fatty acid oxidation on energy utilization: targets and therapy", Curr Pharm Des, 8, pp.1199~1227 (2002)
  88. Sekoguchi E, "A novel mitochondrial carnitine-acylcarnitine translocase induced by partial hepatectomy and fasting", J Biol Chem, 278, pp.38796~38802 (2003)
  89. Camacho JA, "The human and mouse SLC25A29 mitochondrial transporters rescue the deficient ornithine metabolism in fibroblasts of patients with the hyperornithinemiahyperammonemia- homocitrullinuria (HHH) syndrome", Pediatr Res, 66, pp.35~41 (2009)
  90. Hirsch HA, "A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases", Cancer Cell, 17, pp.348~361 (2010)
  91. Menendez JA, "Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis", Nat Rev Cancer, 7, pp.763~777 (2007)
  92. Warburg O, "On the origin of cancer cells", Science, 123, pp.309~314 (1956)
  93. Kim I, "Targeting the AMP-activated protein kinase for cancer prevention and therapy", Front Oncol, 3, pp.175~ (2013)
  94. Ben Sahra I, "Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1", Cancer Res, 71, pp.4366~4372 (2011)
  95. Nair V, "Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors", J Biol Chem, 289, pp.27692~27701 (2014)
  96. Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action", J Clin Invest, 108, pp.1167~1174 (2001)
  97. Sinnett SE, "Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators", Pharmacol Ther, 143, pp.111~118 (2014)
  98. Laderoute KR, "SU11248 (sunitinib) directly inhibits the activity of mammalian 5’-AMP-activated protein kinase (AMPK)", Cancer Biol Ther, 10, pp.68~76 (2010)
  99. Steinberg GR, "Cytokine Regulation of AMPK signalling", Front Biosci (Landmark Ed), 14, pp.1902~1916 (2009)
  100. 전상민, "The double-edged sword of AMPK signaling in cancer and its therapeutic implications", Archives of Pharmacal Research, 38(3), pp.346~357 (2015), 대한약학회

관련 논문AI추천

Controls of Nuclear Factor-Kappa B Signaling Activity by 5’-AMP-Activated Protein Kinase Activation With Examples in Human Bladder Cancer Cells김진, 강주희, 박창신, 이다현, 최보화대한배뇨장애요실금학회 · International Neurourology Journal2016 · 제20권 제3호Hypoxia-Induced Suppression of Antiapoptotic Bcl-2 Expression in Human Bladder Tumor Cells Is Regulated by Caveolin-1-Dependent Adenosine Monophosphate-Activated Protein Kinase Activity박창신, 이다현, 조태진, 최보화, Helen K. Shinn대한배뇨장애요실금학회 · International Neurourology Journal2021 · 제25권 제2호The Metabolic Interaction Between Exercise and Cancer: Focus on the mTOR Pathway홍용, 김재오, 조일영한국디지털정책학회 · 디지털정책학회지2025 · 제4권 제4호Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy기현정, 정재호생화학분자생물학회 · BMB Reports2014 · 제47권 제3호Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls강호원, 김예환, 김운재, 김원태, 김자영, 문성권, 박성혁, 윤석중, 이일석, 정필두, 최영득, 최영현, Chunri Yan, Isaac Yi Kim연세대학교의과대학 · Yonsei Medical Journal2016 · 제57권 제4호Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implicationsHall Michael N., Park Sujin생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권

이 간행물의 다른 논문 (10건)

Application of Oncology Research to Resolve a Problem in Neurourology이택pp. 53-54Does Methylphenidate Affect Cystometric Parameters in Spontaneously Hypertensive Rats?최돈경, 정하범, 박근호, 조성태, 김계환pp. 67-73Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic MarkersIsaac Yi Kim, 김예환, 정필두, 김정민, 김선규, 김자영, 김선영, 김은아, 문성권, 김상태, 최영현, 강호원, 김원재, 김원태, 고규영, 최영기, 김동호, 이옥준, Chunri Yan, 윤석중pp. 74-84Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary ResultMustafa Kemal Atilla, Lokman Irkilata, Mustafa Aydin, Hasan Riza Aydin, Hüseyin Cihan Demirel, Mustafa Kadihasanoglupp. 85-89Clinical and Pathological Characteristics of Hard Nodules Resistant to Morcellation During Holmium Laser Enucleation of the Prostate오승준, Songzhe Piao, 이영주, Yue Wang, 추민수, 배정범pp. 90-98
원문 보기